In conclusion, in patients with type 2 diabetes, treatment with SGLT2 inhibitors after myocardial infarction was associated with lower rates of all-cause mortality and first hospitalisation for heart failure when compared to patients treated with standard of care. Here, SLC5A2 is linked to heart failure.